(Screengrab via Youtube)
LOS ANGELES, CA / ACCESSWIRE / May 2, 2017 / Stony Hill Corp. (OTCQB: STNY), a diversified company focused on the cannabis industry, today announced that the Company has formed an Advisory Board (AB) and appointed Dr. James Mulé as its first member. The Advisory Board will be comprised of experienced business and industry professionals to help guide the Company's business and market development.
The Advisory Board will bring valuable relationships, knowledge, and skills to complement the management and board and to help identify and evaluate expansion into multiple areas of the medical cannabis industry. The Advisors will be called upon to provide subject matter expertise and guidance to support the management and Board on specific areas of focus including medical research, regulatory strategy, and other healthcare related opportunities in the cannabis industry.
Chris Bridges, President of Stony Hill, stated, "We are pleased to welcome Dr. James Mulé to our Advisory Board. Dr. Mulé is a prominent and widely recognized expert in the medical field and brings broad expertise in the areas of medical and cancer research. We believe the mutually beneficial relationship will develop new opportunities for Stony Hill. We look forward to benefiting from his extensive knowledge, experience and relationships as we explore new and exciting opportunities in the medical cannabis industry."
Dr. James Mulé commented, "I am delighted to join Stony Hill's advisory board and look forward to assisting its leadership in implementing an innovative and important strategy to address cancer patient benefit, particularly in melanoma. Stony Hill's team and I share a passion for our mission to find new and novel approaches for the prevention and treatment of cancer and I look forward to beginning our collaboration."
About Dr. James Mulé
Dr. Mulé is Associate Center Director, the U.S. Senator Connie Mack (ret.) & Family Endowed Chair for Melanoma Research and Treatment, and Director of Cell-based Therapies at the Moffitt Cancer Center in Tampa, Florida (https://moffitt.org/). He is widely recognized for his research and clinical trial contributions to cancer immunotherapy, particularly in melanoma. His translational work in this area has helped to develop new treatments for advanced cancer patients. Dr. Mulé has published nearly 200 articles and serves on Advisory Boards of numerous biotechnology and pharma companies as well as investment funds (e.g., OncoPep, Fulgent Diagnostics, UbiVac, Lion Biotech, Orpheus Therapeutics, Vault Pharma, Celgene, Select BioVenture Partners, Noble Life Science Partners, KB Capital Management, among others). Dr. Mulé remains a long-standing special government employee to the FDA (CDER and CBER) and the NCI and was Chair of the Cellular, Tissue, and Gene Therapy Advisory Committee of CBER, FDA. He currently serves on the advisory boards of several NCI-designated Cancer Centers and was a member of the NCI Director's Board of Scientific Counselors (BSC-A). Dr. Mulé also serves on the Editorial Boards of several peer-reviewed journals, including Scientific Reports (nature.com), Journal of Immunotherapy, and Cancer Immunology Research (AACR). Dr. Mulé received his professional degrees from the Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, Washington. He then received his formal post-graduate training at the Surgery Branch, Division of Cancer Treatment, National Cancer Institute, NIH, Bethesda, Maryland, where he became a Senior Investigator with tenure. Dr. Mulé moved to Palo Al to, CA, where he helped to launch and scientifically direct two biotechnology companies and was also an adjunct professor at Stanford University. He then moved to Ann Arbor, Michigan to become the Director of the Tumor Immunology and Immunotherapy Program at the University of Michigan Comprehensive Cancer Center, the Maude T. Lane Endo wed Professor of Surgery with tenure, Department of Surgery, and Professor in the Department of Internal Medicine.
About Stony Hill Corp.
Stony Hill Corp. (www.stonyhillcorp.com) is a diversified company focused on multiples areas of the cannabis, hemp and CBD industry. The Company is focused on select investment, branding, real estate, and partnership opportunities in the recreational, health and wellness, nutraceutical, and media industries.
Stony Hill has several strategic partnerships currently in place and is actively pursuing additional partnerships and other strategic growth opportunities.
Safe Harbor Statement
Forward-Looking Statements Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the development and protection of our brands and other intellectual property, the need to raise capital to meet business requirements, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
